Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

September 24, 2026

Study Completion Date

October 1, 2027

Conditions
Colorectal CancerColorectal Neoplasms
Interventions
DRUG

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens

"Nocardia Rubra Cell Wall Skeleton 200 mcg-400 mcg, 0.3 ml diluted in water for injection or lidocaine, was injected subcutaneously every 2 or 3 weeks.~Efficacy was evaluated every 2 cycles according to RECIST 1.1 criteria. Patients are enrolled and given this study regimen of drugs on top of their prior second- or third-line regimen until disease progression or intolerable toxicities occur; or the patient requests to be discharged."

Trial Locations (1)

210029

RECRUITING

the First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Sun Jing

OTHER